Key facts
- Silver Creek Pharmaceuticals’s last known valuation is $60.0M (Feb 2018).
- It has raised $57.1M across 2 recorded rounds; the latest was Early Stage VC ($9.2M) in Jan 2022.
- Notable investors include Catalytik Group, Crocker Ventures, Lung, Mark Agne, National Heart — 8 tracked in total.
- Silver Creek Pharmaceuticals has filed 2 Form Ds with the SEC since 2016, most recently Feb 2022 ($9.2M sold to 22 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Silver Creek Pharmaceuticals
Funding rounds
2 roundsAbout Silver Creek Pharmaceuticals
Operator of a biotechnology firm intended to develop therapies that improve the body's healing response and repair damaged tissue. The company offers novel regenerative medicines that stimulate stem cell-based regeneration of cardiovascular tissues after a cardiac infarction, providing patients with the required therapies to protect or repair heart tissue following a heart attack.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2010
- Employees
- 8
- Website
- silvercreekpharma.com/
- Ownership
- Privately Held (backing)
Silver Creek Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Silver Creek Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Silver Creek Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.